University of Kansas
Welcome,         Profile    Billing    Logout  
 16 Trials 
32 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kim, Han W
NCT06491030: Post-Operative Thoracolumosacral Orthosis for PJK

Recruiting
4
84
US
Align PJK™ TLSO brace, Standard of Care
Hospital for Special Surgery, New York, Aspen Medical Products
Proximal Junctional Kyphosis, Adult Spinal Deformity Surgery, Thoracolumbosacral Orthosis
12/25
12/26
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years

Recruiting
3
249
RoW
DTaP-IPV combination vaccine
Boryung Biopharma Co., Ltd.
Diphtheria, Tetanus, Pertussis, Poliomyelitis
12/20
07/21
PEARLY, NCT02441933: Carboplatin in EARLY Triple Negative Breast Cancer Trial ( Trial)

Active, not recruiting
3
878
RoW
taxane plus carboplatin, Taxane
Yonsei University
Breast Cancer
06/25
06/25
NCT03553186: Tranexamic Acid in Adult Spinal Deformity Surgery

Recruiting
3
100
US
Tranexamic Acid 100 MG/ML, Intervention group, Placebo, Control group
Hospital for Special Surgery, New York
Spinal Deformity, Degenerative Lumbar Spinal Stenosis, Blood Loss, Surgical
03/25
03/25
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05819658: GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)

Completed
2
78
RoW
GV1001 Placebo, Normal saline, GV1001 0.56mg, Tertomotide 0.84mg, GV1001 1.12mg, Tertomotide 1.68mg
GemVax & Kael
Progressive Supranuclear Palsy
10/24
10/24
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

Terminated
2
139
Europe, RoW
Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1
Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie
HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer
11/24
11/24
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
CADS, NCT04194138: Complex Adult Deformity Surgery

Recruiting
N/A
500
Canada, US
Index or spine revision surgery for complex adult spinal deformity
International Spine Study Group Foundation, Medtronic, Globus Medical Inc, SI-BONE, Inc.
Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
12/31
07/32
NCT01745237: Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis

Recruiting
N/A
27000
US
Duke University
Sarcoidosis
06/32
06/32
PCD 2, NCT04194996: Radiographic and Clinical Evaluation of Surgical Treatment for Cervical Deformity: A Multi-Center Study 2.0

Recruiting
N/A
200
US
Surgical intervention
International Spine Study Group Foundation, DePuy Synthes, Orthofix Inc.
Cervical Deformity
12/32
07/33
NCT04888104: Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

Recruiting
N/A
225
US
Index or revision spine surgery for complex adult spinal deformity, VersaTie System
International Spine Study Group Foundation, NuVasive
Adult Spinal Deformity, Scoliosis, Kyphosis
12/34
12/34
Portell, Craig A
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
EA4151, NCT03267433: Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Active, not recruiting
3
689
US, RoW
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Mantle Cell Lymphoma
01/27
01/27
PrE0403, NCT03113422: Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Completed
2
56
US
Induction Venetoclax, GDC-0199, ABT-199, RO5537382, Maintenance Venetoclax
PrECOG, LLC., Genentech, Inc.
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
05/21
01/23
PrE0405, NCT03834688: Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

Completed
2
33
US
Venetoclax, GDC-0199, ABT-199, RO5537382, Bendamustine, Bendamustine hydrochloride, Rituximab, Chimeric anti-CD20 monoclonal antibody, Rituxan
PrECOG, LLC., Genentech, Inc.
Mantle Cell Lymphoma
10/22
07/24
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
06/26
06/28
EA4181, NCT04115631: A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Active, not recruiting
2
360
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Bendamustine, SDX-105, Bendamustine Hydrochloride, Bendamustin Hydrochloride, Bendeka, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treanda, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Liver Lymphoma, Mantle Cell Lymphoma
12/25
12/25
NCT05404945: Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

Recruiting
2
44
US
Pembrolizumab, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine, Brentuximab vedotin
University of Virginia, Merck Sharp & Dohme LLC
Classical Hodgkin Lymphoma
10/27
10/27
NCT03240211: Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Recruiting
1
37
US
Pembrolizumab, Keytruda, Pralatrexate, Folotyn, Decitabine, Dacogen
University of Virginia, Merck Sharp & Dohme LLC, Otsuka Pharmaceutical Development & Commercialization, Inc.
PTCL, CTCL
06/25
12/25
Hoffman, Marc
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
Bradshaw, Sharon
NCT03295981: Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Recruiting
3
120
Canada, US, RoW
Zoledronic Acid, zoledronate
St. Louis University, Orthopedic Research and Education Foundation, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), University of Iowa, Johns Hopkins University, McGill University Health Centre/Research Institute of the McGill University Health Centre, The Cleveland Clinic, Wake Forest University, University of Kansas, Indiana University, University of Oklahoma, Beth Israel Deaconess Medical Center, Boston Children's Hospital, American Academy of Orthopaedic Surgeons, Massachusetts General Hospital, All India Institute of Medical Science, University of Washington, University of California
Giant Cell Tumor of Bone
01/26
01/27
NCT06259409: Regenn® Therapy System Safety Study

Recruiting
1
30
US
Regenn® Negative Pressure Therapy System, NPWT, Negative Pressure Wound Therapy, Prevena™ Incision Management System
Progenerative Medical, Inc
Surgical Wound
10/25
10/25
NCT00825409: Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Recruiting
N/A
203
US
Carbon Modular Radial Head, Ascension CMRH, Metal Radial Head, Ascension MRH
Ascension Orthopedics, Inc.
Degenerative Arthritis, Post-Traumatic Arthritis, Rheumatoid Arthritis
01/15
07/15
NCT05692687: A Post-market Clinical Study to Evaluate the Safety and Performance of the Carbon Fibre Reinforced Polyetheretherketone Metatarso-Phalangeal (MTP) Plate (CoLink® PCR MTP Plate) for the Treatment of Hallux Rigidus

Recruiting
N/A
40
US
Invibio Ltd, In2Bones
Hallux Rigidus
07/24
11/25
NCT06107959: Changes in Resting Metabolic Rate Following Orthopedic Surgery

Recruiting
N/A
100
US
Pre-surgical nutrition, hydration, RMR, and body composition assessments, Post-surgical nutrition, hydration, RMR and body composition assessments
University of Kansas Medical Center
Metabolism; Disorder, Postprocedural, Resting Metabolic Rate, Post Operative Nutrition
06/25
12/25
Sweeney, Kyle
NCT04347122: Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction

Completed
4
16
US
Tranexamic Acid (TXA)
University of Kansas Medical Center
Musculoskeletal Cancer, Sarcoma,Soft Tissue
08/23
08/23
NCT03295981: Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Recruiting
3
120
Canada, US, RoW
Zoledronic Acid, zoledronate
St. Louis University, Orthopedic Research and Education Foundation, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), University of Iowa, Johns Hopkins University, McGill University Health Centre/Research Institute of the McGill University Health Centre, The Cleveland Clinic, Wake Forest University, University of Kansas, Indiana University, University of Oklahoma, Beth Israel Deaconess Medical Center, Boston Children's Hospital, American Academy of Orthopaedic Surgeons, Massachusetts General Hospital, All India Institute of Medical Science, University of Washington, University of California
Giant Cell Tumor of Bone
01/26
01/27
Wurtz, LDaniel
NCT03295981: Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

Recruiting
3
120
Canada, US, RoW
Zoledronic Acid, zoledronate
St. Louis University, Orthopedic Research and Education Foundation, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), University of Iowa, Johns Hopkins University, McGill University Health Centre/Research Institute of the McGill University Health Centre, The Cleveland Clinic, Wake Forest University, University of Kansas, Indiana University, University of Oklahoma, Beth Israel Deaconess Medical Center, Boston Children's Hospital, American Academy of Orthopaedic Surgeons, Massachusetts General Hospital, All India Institute of Medical Science, University of Washington, University of California
Giant Cell Tumor of Bone
01/26
01/27

Download Options